235 related articles for article (PubMed ID: 38429261)
1. CD8
Palmeri JR; Lax BM; Peters JM; Duhamel L; Stinson JA; Santollani L; Lutz EA; Pinney W; Bryson BD; Dane Wittrup K
Nat Commun; 2024 Mar; 15(1):1900. PubMed ID: 38429261
[TBL] [Abstract][Full Text] [Related]
2. Tregs constrain CD8
Palmeri JR; Lax BM; Peters JM; Duhamel L; Stinson JA; Santollani L; Lutz EA; Pinney W; Bryson BD; Wittrup KD
bioRxiv; 2023 Feb; ():. PubMed ID: 36778460
[TBL] [Abstract][Full Text] [Related]
3. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
Freeman ZT; Nirschl TR; Hovelson DH; Johnston RJ; Engelhardt JJ; Selby MJ; Kochel CM; Lan RY; Zhai J; Ghasemzadeh A; Gupta A; Skaist AM; Wheelan SJ; Jiang H; Pearson AT; Snyder LA; Korman AJ; Tomlins SA; Yegnasubramanian S; Drake CG
J Clin Invest; 2020 Mar; 130(3):1405-1416. PubMed ID: 32015231
[TBL] [Abstract][Full Text] [Related]
4. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
5. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
[TBL] [Abstract][Full Text] [Related]
6. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.
Lin GH; Liu Y; Ambagala T; Kwon BS; Ohashi PS; Watts TH
PLoS One; 2010 Jun; 5(6):e11003. PubMed ID: 20543982
[TBL] [Abstract][Full Text] [Related]
8. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of cancer with 4-1BB.
Vinay DS; Kwon BS
Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
[TBL] [Abstract][Full Text] [Related]
10. Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.
Wang Y; Zhang X; Xu C; Nan Y; Fan J; Zeng X; Kwon BS; Ju D
Front Immunol; 2022; 13():1004475. PubMed ID: 36544785
[TBL] [Abstract][Full Text] [Related]
11. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.
Chen S; Fan J; Zhang M; Qin L; Dominguez D; Long A; Wang G; Ma R; Li H; Zhang Y; Fang D; Sosman J; Zhang B
Nat Commun; 2019 Jan; 10(1):150. PubMed ID: 30635578
[TBL] [Abstract][Full Text] [Related]
12. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
13. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
14. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
15. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge.
Kim HY; Choi JH; Haque MM; Park JH; Kim IH; Choi BK; Lee A; Park S
Cancer Immunol Immunother; 2022 Apr; 71(4):967-978. PubMed ID: 34988585
[TBL] [Abstract][Full Text] [Related]
17. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity.
Akhmetzyanova I; Zelinskyy G; Littwitz-Salomon E; Malyshkina A; Dietze KK; Streeck H; Brandau S; Dittmer U
J Immunol; 2016 Jan; 196(1):484-92. PubMed ID: 26608920
[TBL] [Abstract][Full Text] [Related]
18. Chronic activation of 4-1BB signaling induces granuloma development in tumor-draining lymph nodes that is detrimental to subsequent CD8
Kim SH; Singh R; Han C; Cho E; Kim YI; Lee DG; Kim YH; Kim SS; Shin DH; You HJ; Lee HW; Kwon BS; Choi BK
Cell Mol Immunol; 2021 Aug; 18(8):1956-1968. PubMed ID: 32868911
[TBL] [Abstract][Full Text] [Related]
19. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
Liu G; Luo P
Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
